Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Open accessAbstract
In order to investigate the biologic processes underlying and resulting from the megakaryocytic hyperplasia that characterizes idiopathic myelofibrosis (IMF), peripheral blood CD34+ cells isolated from patients with IMF, polycythemia vera (PV), and G-CSF–mobilized healthy volunteers were cultured in the presence of stem cell factor and thrombopoietin. IMF CD34+ cells generated 24-fold greater numbers of megakaryocytes (MKs) than normal CD34+ cells. IMF MKs were also shown to have a delayed pattern of apoptosis and to overexpress the antiapoptotic protein bcl-xL. MK hyperplasia in IMF is, therefore, likely a consequence of both the increased ability of IMF progenitor cells to generate MKs and a decreased rate of MK apoptosis. Media conditioned (CM) by CD61+ cells generated in vitro from CD34+ cells were then assayed for the levels of growth factors and proteases. Higher levels of transforming growth factor-β (TGF-β) and active matrix metalloproteinase-9 (MMP9) were observed in media conditioned with IMF CD61+ cells than normal or PV CD61+ cells. Both normal and IMF CD61+ cells produced similar levels of VEGF. MK-derived TGF-B and MMP-9, therefore, likely contribute to the development of many pathological epiphenomena associated with IMF.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CD9 and VWF are closely associated with MkP differentiation.
“In the MkPs, we identified a downregulation of CD9 and VWF , closely associated with MkP differentiation 46-49 , upon IFNa treatment ( Supplementary Fig. 4b ) which is consistent with the decrease in the proportion of MkP observed after IFNa treatment.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [48]
In MkPs, CD9 and VWF were downregulated upon IFNa treatment.
“In the MkPs, we identified a downregulation of CD9 and VWF , closely associated with MkP differentiation 46-49 , upon IFNa treatment ( Supplementary Fig. 4b ) which is consistent with the decrease in the proportion of MkP observed after IFNa treatment.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [48]
Cited by
Sorted by citations
Somatic mutations and cell identity linked by Genotyping of Transcriptomes
Nam, A. S., Kim, K.-T., Chaligne, R., Izzo, F., Ang, C., Taylor, J., Myers, R. M., Abu-Zeinah, G., Brand, R., Omans, N. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1367-0 · Cited by 333 · see citing works
Self-citationBadalucco, S., Di Buduo, C. A., Campanelli, R., Pallotta, I., Catarsi, P., Rosti, V., Kaplan, D. L., Barosi, G., Massa, M., & Balduini, A. (2013) · Haematologica · doi:10.3324/haematol.2012.076752 · Cited by 37 · see citing works
Self-citationGleitz, H. F., Kramann, R., & Schneider, R. K. (2018) · The Journal of Pathology · doi:10.1002/path.5078 · Cited by 23 · see citing works
Type 1 interferon perturbates clonal competition by reshaping human blood development
Lama, C., Isakov, D., Rosenberg, S., Quijada-Álamo, M., Saurty-Seerunghen, M. S., Moein, S., Nozais, M., Abera, T.-A., Sakaguchi, O., Totwani, M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02751-3 · Cited by 3 · see citing works
Self-citation
- Authors
- Ciurea, S. O., Merchant, D., Mahmud, N., Ishii, T., Zhao, Y., Hu, W., Bruno, E., Barosi, G., Xu, M., & Hoffman, R.
- Affiliations
- University of Illinois Chicago (US)
- University of Illinois College of Medicine at Chicago, Hematology/Oncology Section, Department of Medicine, Chicago;
- Policlinico San Matteo Fondazione (IT)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-08-01
- Volume
- 110
- Issue
- 3
- Pages
- 986-993
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC1924766
- OpenAlex
- W2052033797
- Cited by
- 213
- References
- 0
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 19 · 2021: 15 · 2020: 14 · 2019: 16 · 2018: 11 · 2017: 15 · 2016: 11 · 2015: 10 · 2014: 6 · 2013: 10 · 2012: 9
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Illinois at Urbana-Champaign
- National Cancer Institute (P01CA108671)
- Topics
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- primary myelofibrosis, megakaryocytes, megakaryocytic hyperplasia, CD34+ cells, apoptosis, Bcl-xL, polycythemia vera, stem cell factor, thrombopoietin, TGF-beta, MMP-9, vascular endothelial growth factor
- MeSH terms
- Adult, Aged, Cells, Cultured, Female, Hematopoietic Stem Cells, Humans, Hyperplasia, Male, Megakaryocytes, Middle Aged, Polycythemia Vera, Thrombopoietin, Granulocyte Colony-Stimulating Factor, Transforming Growth Factor beta, Culture Media, Conditioned, Apoptosis, Antigens, CD34, Hematopoietic Stem Cell Mobilization, Matrix Metalloproteinase 9, Integrin beta3, Vascular Endothelial Growth Factor A, bcl-X Protein, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review